Sana Biotechnology Partners with Mayo Clinic to Advance SC451 Development
Sana Biotechnology and Mayo Clinic announced a strategic collaboration to advance development of SC451, Sana's investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. SC451 is designed to allow a single administration of pancreatic islet cells to support long-term glucose control without the need for ongoing insulin therapy or immunosuppression for patients with type 1 diabetes. The collaboration will draw on Mayo Clinic's multidisciplinary expertise to accelerate the development, validation, and standardization of protocols and processes for SC451, supporting safe, scalable, and consistent delivery across diverse clinical environments.
